• AI Grand Rounds
  • Posts
  • AI at the Olympics: Game-Changing Technologies for 2024

AI at the Olympics: Game-Changing Technologies for 2024

AI-Driven Innovations in Sports Medicine and Injury Prevention

In partnership with

Fellow Healthcare Champions,

Are you overwhelmed by all the fluff and hype around AI and not sure how to identify meaningful information? We get it. As busy clinicians ourselves, our newsletter, "AI Grand Rounds," is here to provide clinically relevant AI information.

No matter who you are—a healthcare provider, inventor, investor, or curious reader—we PROMISE one thing: you will always find information that is relevant, meaningful, and balanced.

Let’s join our journey to share clinically meaningful and relevant knowledge on healthcare AI.

Sincerely,

Your fellow physicians!

Table of Contents

🚨 Pulse of Innovation 🚨

Breaking news in the healthcare AI

Three ways AI is changing the 2024 Olympics for athletes and fans

AI is poised to revolutionize the Paris 2024 Olympics, providing substantial benefits to athletes and fans:

  • Athlete Assistance: The Athlete365 app, featuring AthleteGPT, offers 24/7 support. It answers queries about schedules and locations and provides personalized training and recovery advice. This ensures athletes are well-informed and can focus on their performance.

  • Training Enhancement: Intel's 3D Athlete Tracking (3DAT) technology uses advanced biomechanics analysis to optimize training. This helps athletes fine-tune their techniques and improve their performance through precise feedback.

  • Refereeing and Viewer Experience: AI supports referees by analyzing real-time data to ensure fair play. AI generates personalized highlights and enriched statistics for fans, enhancing the viewing experience with tailored content.

Challenges: Ensuring the accuracy of AI-generated data and addressing privacy concerns related to the extensive data collection are critical issues that need to be managed.

🧑🏼‍🔬 Bench to Bedside👨🏽‍🔬

Developments in healthcare AI research and innovations

Autonomous AI for Diabetic Eye Disease: A Step Closer to Equity in Healthcare

  • Diabetic Eye Disease (DED) - retinopathy is the most common cause of vision loss, and screening guidelines exist for diabetic adults for early identification and management of the disease. However, the rates of screening and adherence to guidelines are historically low.

  • The Nature Digital article from Johns Hopkins showed that implementing autonomous artificial intelligence-based DED screening improved screening and adherence overall. The study was a retrospective analysis of 17,000 patients.

  • The pre-AI rates were 45% which increased to 54% overall, and these rates increased from 44% to 57% in the African-American population. Thus, autonomous AI-based screening improved the screening rates in historically underserved populations. A similar increase was observed in the Native American population as well.

  • All the patients used the FDA-approved LumineticsCore AI system, which was used at various primary care sites across the John Hopkins system.

Learn AI-led Business & startup strategies, tools, & hacks worth a Million Dollars (free AI Masterclass) 🚀

This incredible 3-hour Crash Course on AI & ChatGPT (worth $399) designed for founders & entrepreneurs will help you 10x your business, revenue, team management & more.

It has been taken by 1 Million+ founders & entrepreneurs across the globe, who have been able to:

  • Automate 50% of their workflow & scale your business

  • Make quick & smarter decisions for their company using AI-led data insights

  • Write emails, content & more in seconds using AI

  • Solve complex problems, research 10x faster & save 16 hours every week

🧑🏽‍⚕️ AI in Clinic 🏥

Developments in healthcare AI research and innovations

Diagnosing Diabetic Eye Disease at Point of Care: LumineticsCore

About 60,000 patients are blinded every year due to diabetic retinopathy, which can be effectively managed by early screening and continuous regular follow-up eye exams. As described in the article in the previous section, “Bench to bedside”, adherence to the eye exam is low, and autonomous diagnostics can be instrumental.

  • The LumineticsCore uses the same machine and camera that eye doctors use to screen retinal lesions. It also uses the same markers and methods to determine the presence or absence of retinal lesions.

  • Once the determination is done, the patients with negative findings are re-screened at 12 months, and patients with positive findings are referred to the eye specialist. This AI-based diagnostic is highly accurate and does not require additional validation from a specialist. Watch video

🤖 Patient First, AI Second🤖

Ethical and Regulatory Landscape of Healthcare AI

Ethics in AI: How can you learn more, below are free courses

  • Ethics of AI by the University of Helsinki

    • This is a free online course covering key concepts in AI, such as non-maleficence, accountability, transparency, human rights, and fairness.

  • UMontrealX: Bias and Discrimination in AI

    • Discover how even computer algorithms may be biased and have a serious impact on our everyday lives. In this MOOC, based on an IVADO School involving various international experts, you will learn how to identify and alleviate bias and discrimination in Artificial Intelligence.

  • Ethical AI by Udacity

    • This will focus on defining ethical AI and outlining ethical AI principles. It will also teach how to apply ethics to AI lifecycles and share case studies to drive the point home.

  • Ethics of AI by Coursera

    • This is a beginner-level course that takes around ~ 10 hours to finish. It focuses on how reasons for ethical analysis are applied to AI and identifies the ethical and social impacts and implications of AI.

Disclaimer: This newsletter contains opinions and speculations and is based solely on public information. It should not be considered medical, business, or investment advice. This newsletter's banner and other images are created for illustrative purposes only. All brand names, logos, and trademarks are the property of their respective owners. At the time of publication of this newsletter, the author has no business relationships, affiliations, or conflicts of interest with any of the companies mentioned except as noted. ** OPINIONS ARE PERSONAL AND NOT THOSE OF ANY AFFILIATED ORGANIZATIONS!

Reply

or to participate.